Phage-Therapy Resistance, Manufacturing and Regulatory Translation Study
A completed bacteriophage translation study connecting host specificity and resistance to manufacturing, quality attributes, formulation, clinical evidence and regulation.

Project definition
Problem statement
A bacteriophage can kill a bacterial isolate in a laboratory assay while still being unsuitable as a controlled medicinal product.
The biotechnology problem is to connect host specificity and resistance to production hosts, seed lots, purification, potency, formulation, clinical evidence and lifecycle regulation.
Project objectives
- Compare fixed, personalized, magistral, adjunct, route-specific and engineered phage-product strategies.
- Model eight infection scenarios, five regulatory regimes and four evidence positions.
- Evaluate eight resistance mechanisms and fourteen critical quality attributes.
- Build a manufacturing FMEA across eleven unit operations.
- Quantify strategy uncertainty with 20,000 fixed-seed samples per strategy.
- Retain complete results, figures, tests, references and editable documentation.
Project structure
Project components
Product strategy model
Compares ten fixed, personalized, magistral, adjunct, oral, inhaled, topical, intravenous and engineered concepts.
Resistance model
Tracks receptor change, masking, intracellular defence, physiological limitation and spatial refuge.
Manufacturing model
Connects host and seed control to propagation, purification, blending, sterile processing and storage.
Quality model
Ranks identity, genome, potency, host range, purity, sterility, compatibility and stability evidence gaps.
Regulatory crosswalk
Compares declared product-model fit across the EU, UK, US, Belgium and India.
Verification pipeline
Regenerates the study, tests the model, validates the package and reproduces it in Docker.
Methodology
Project workflow
- 01Define the product
Choose a strategy, intended infection, route, update model and regulatory regime.
- 02Evaluate resistance
Compare host coverage, cocktail architecture and residual resistance mechanisms.
- 03Evaluate manufacture
Review host, seed, process, impurity, blending, fill and storage risks.
- 04Evaluate translation
Compare analytical maturity, formulation, delivery, clinical evidence and pathway fit.
- 05Test uncertainty
Inspect factorial, sensitivity and Monte Carlo results before drawing a conclusion.
Demonstration scenario
Under the declared central positions, the fixed natural-phage topical cocktail has the highest composite score of 40.7289. Personalized products improve matching and update agility, while engineered products carry larger characterization and pathway burdens.
Engineering
Tools and method
- Tools
- The project uses Python 3.12, NumPy, pandas, Matplotlib for subject analysis, simulation, and results.
- Declared inputs
- Python data structures retain every normalized engineering position and evidence boundary.
- Deterministic analysis
- NumPy and pandas generate 1,600 strategy, scenario, regime and evidence cases.
- Risk analysis
- Resistance, CQA and FMEA tables expose biological, process and analytical priorities.
- Uncertainty
- Fixed-seed Monte Carlo and one-factor sensitivity analysis test ranking stability.
- Evidence
- CSV, JSON, PNG, PDF and Word files retain the complete analysis and report.
Testing
Evaluation
Evaluation measures
- Composite translation-readiness score by strategy and scenario
- Residual resistance across four evidence positions
- Manufacturing readiness, update agility, turnaround and process risk
- CQA evidence gaps and manufacturing FMEA priorities
- Regulatory fit across five declared regimes
- Monte Carlo intervals and one-factor sensitivity
Project boundaries
- All numerical inputs are normalized engineering evidence positions.
- The study does not establish clinical efficacy, patient suitability or a treatment recommendation.
- The FMEA does not define a manufacturing release decision or specification.
- The regulatory crosswalk is not legal advice or evidence of approval.
- Experimental and authority validation are required before operational use.
Included
- 01Complete Python source and declared study configuration
- 021,600 factorial translation cases
- 03Eight resistance mechanisms and fourteen critical quality attributes
- 04154-cell manufacturing FMEA and regulatory crosswalk
- 05Twelve generated figures and one attributed literature figure
- 0673-page project report in PDF and editable Word formats
- 0715-page project and defence guide in PDF and editable Word formats
- 08Sixty-six annotated references with evidence boundaries
- 09Automated tests, repository validation and Docker reproduction
Project record
No information is collected on this page.
- Permanent project ID
- GP-BT-0LC2FJL
- Catalogued
- 21 Aug 2026
- Completed
- 30 Aug 2026
- Verified
- 30 Aug 2026
- Demonstration
- Included in repository
Handover
After purchase
- 01Payment is confirmed
The project is marked unavailable and cannot be purchased again.
- 02Repository access is granted
The buyer's submitted GitHub account receives access to the private repository.
- 03The purchase record is delivered
The certification sheet is prepared from the reviewed buyer details and sent privately by email.